IKT
Income statement / Annual
Last year (2024), Inhibikase Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Inhibikase Therapeutics, Inc.'s net income was -$27.52 M.
See Inhibikase Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$260.50 K |
$123.44 K |
$3.10 M |
$698.47 K |
$1.12 M |
$4.04 M |
$2.06 M |
$967.39 K |
| Cost of Revenue |
$0.00
|
$13.62 M
|
$6.72 K
|
$11.36 M
|
$893.80 K
|
$2.55 M
|
$3.65 M
|
$1.76 M
|
$846.39 K
|
| Gross Profit |
$0.00
|
-$13.36 M
|
$116.72 K
|
-$8.26 M
|
-$195.33 K
|
-$1.43 M
|
$393.85 K
|
$305.25 K
|
$121.00 K
|
| Gross Profit Ratio |
0
|
-51.28
|
0.95
|
-2.66
|
-0.28
|
-1.27
|
0.1
|
0.15
|
0.13
|
| Research and Development Expenses |
$17.21 M
|
$13.62 M
|
$12.03 M
|
$11.36 M
|
$893.80 K
|
$2.55 M
|
$3.65 M
|
$1.76 M
|
$846.39 K
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.52 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.38 M
|
$6.73 M
|
$6.22 M
|
$6.51 M
|
$2.62 M
|
$4.27 M
|
$2.52 M
|
$710.38 K
|
$734.29 K
|
| Other Expenses |
$0.00
|
-$13.62 M
|
-$123.44 K
|
-$3.10 M
|
-$698.47 K
|
-$1.12 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$28.56 M
|
$6.73 M
|
$18.13 M
|
$14.77 M
|
$2.82 M
|
$5.70 M
|
$2.12 M
|
$2.47 M
|
$734.29 K
|
| Cost And Expenses |
$28.59 M
|
$20.35 M
|
$18.13 M
|
$14.77 M
|
$2.82 M
|
$5.70 M
|
$2.12 M
|
$2.47 M
|
$1.58 M
|
| Interest Income |
$1.07 M
|
$1.06 M
|
$74.45 K
|
$19.92 K
|
$29.40 K
|
$24.84 K
|
$0.00
|
$30.95 K
|
$15.45 K
|
| Interest Expense |
$0.00
|
$0.00
|
$74.45 K
|
$19.92 K
|
$29.40 K
|
$24.84 K
|
$30.33 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$26.27 K
|
$177.40 K
|
$6.72 K
|
$14.77 M
|
$2.82 M
|
$5.70 M
|
$2.12 M
|
$405.13 K
|
$613.29 K
|
| EBITDA |
-$27.49 M |
-$19.91 M |
-$18.12 M |
-$14.77 M |
-$2.82 M |
-$5.70 M |
$0.00 |
$0.00 |
$0.00 |
| EBITDA Ratio |
0
|
-76.44
|
-146.81
|
-4.76
|
-4.04
|
-5.08
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-77.12
|
-146.86
|
-4.76
|
-4.04
|
-5.08
|
-0.53
|
-0.2
|
-0.63
|
| Total Other Income/Expenses Net |
$1.07 M
|
$1.06 M
|
$74.45 K
|
-$19.92 K
|
-$29.40 K
|
-$24.84 K
|
-$30.33 K
|
-$30.95 K
|
-$15.45 K
|
| Income Before Tax |
-$27.52 M
|
-$19.03 M
|
-$18.05 M
|
-$14.79 M
|
-$2.85 M
|
-$5.72 M
|
-$2.15 M
|
-$436.08 K
|
-$628.74 K
|
| Income Before Tax Ratio |
0
|
-73.05
|
-146.26
|
-4.77
|
-4.08
|
-5.1
|
-0.53
|
-0.21
|
-0.65
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$148.91 K
|
$19.92 K
|
$29.40 K
|
$24.84 K
|
-$161.14 K
|
-$405.13 K
|
-$15.45 K
|
| Net Income |
-$27.52 M
|
-$19.03 M
|
-$17.91 M
|
-$14.81 M
|
-$2.88 M
|
-$5.75 M
|
-$2.15 M
|
-$436.08 K
|
-$628.74 K
|
| Net Income Ratio |
0
|
-73.05
|
-145.05
|
-4.78
|
-4.12
|
-5.12
|
-0.53
|
-0.21
|
-0.65
|
| EPS |
-1.16 |
-3.57 |
-4.26 |
-4.88 |
-1.72 |
-3.34 |
-1.61 |
-0.25 |
-0.48 |
| EPS Diluted |
-1.16 |
-3.57 |
-4.26 |
-4.88 |
-1.72 |
-3.34 |
-1.61 |
-0.25 |
-0.48 |
| Weighted Average Shares Out |
$23.71 M
|
$5.33 M
|
$4.20 M
|
$3.03 M
|
$1.68 M
|
$1.72 M
|
$1.34 M
|
$1.72 M
|
$1.30 M
|
| Weighted Average Shares Out Diluted |
$23.71 M
|
$5.33 M
|
$4.20 M
|
$3.03 M
|
$1.68 M
|
$1.72 M
|
$1.34 M
|
$1.72 M
|
$1.30 M
|
| Link |
|
|
|
|
|
|
|
|
|
